To investigate whether the superior therapeutic efficacy observed in Trp2.Combo-treated mice compared to Ifna.Il12 was associated with generation of tumor-specific CD8+ T cells, we performed an IFNγ ELISPOT assay on CD8+ T cells purified from the spleens of treated mice. Here, CD8A is linked to neoplasm.